Galectin Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Galectin Therapeutics generated cash of -$32,965,000, which is less than the previous year. Cash used in financing activities reached the amount of $40,033,000 last year. Net change in cash is therefore $7,068,000.
Cash Flow
| 2014 | -12.42M | -400K | 31.46M |
|---|---|---|---|
| 2015 | -16.98M | -400K | 13.70M |
| 2016 | -16.40M | 0 | 5.92M |
| 2017 | -15.89M | 0 | 3.58M |
| 2018 | -10.17M | 0 | 15.37M |
| 2019 | -10.84M | 0 | 50.07M |
| 2020 | -20.60M | 0 | 263K |
| 2021 | -24.30M | 0 | 36.81M |
| 2022 | -31.05M | 0 | 10M |
| 2023 | -32.96M | 0 | 40.03M |
GALT Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 18.59M | 39.64M | 27.14M | 47.48M | 8.25M | 3.05M | 15.36M | 25.84M | 29.12M | 10.48M |
Operating activities | ||||||||||
Net income | -41.06M | -38.77M | -30.52M | -23.46M | -13.29M | -13.9M | -16.23M | -21.43M | -20.02M | -15.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 33K | 32K | 41K | 36K | 35K | 0 | 1K | 7K | 7K | 10K |
Stock-based compensation expense | 2.26M | 2.86M | 2.07M | 1.79M | 1.68M | 0 | 1.10M | 2.47M | 3.4M | 4.07M |
| Deferred income tax benefit | 2.26M | 2.86M | 2.07M | 1.79M | 1.68M | 0 | 1.10M | 2.47M | 3.4M | 4.07M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.67M | 4.24M | 3.68M | 2.53M | 997K | -1.09M | -812K | 2.41M | -783K | -783K |
Cash generated by operating activities | -32.96M | -31.05M | -24.30M | -20.60M | -10.84M | -10.17M | -15.89M | -16.40M | -16.98M | -12.42M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -400K |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -400K |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -400K | -400K |
Financing activities | ||||||||||
Common Stock Issued | 40.03M | 10M | 6.81M | 263K | 50.46M | 15.37M | 3.58M | 5.92M | 13.70M | 29.33M |
Payments for dividends | 0 | -97K | 0 | 0 | -394K | 0 | -1.23M | 0 | -943K | 0 |
Repurchases of common stock | 671K | 899K | -30M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 30M | 10M | -30M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 40.03M | 10M | 36.81M | 263K | 50.07M | 15.37M | 3.58M | 5.92M | 13.70M | 31.46M |
Net Change In Cash | 7.06M | -21.05M | 12.50M | -20.33M | 39.22M | 5.2M | -12.30M | -10.48M | -3.28M | 18.63M |
Cash at end of period | 25.66M | 18.59M | 39.64M | 27.14M | 47.48M | 8.25M | 3.05M | 15.36M | 25.84M | 29.12M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |